Half Year 2018 Shield Therapeutics PLC Earnings Call

19/9/2018 6:30

Conference Call Shield Therapeutics PLC

Shield Therapeutics PLC Conference call will be held on 19-Sep-2018. During the earnings conference call's session Shield Therapeutics PLC will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Shield Therapeutics PLC for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Read more Conference Call

Shield Therapeutics PLC (STXS.L)

Shield Therapeutics PLC 3rd Fl Baltic Business Quarters, Abbott GATESHEAD NE8 3D P: +44191.5118500